HK1040633A1 - Method of administering a compound to multi-drug resistant cells - Google Patents
Method of administering a compound to multi-drug resistant cellsInfo
- Publication number
- HK1040633A1 HK1040633A1 HK02102308A HK02102308A HK1040633A1 HK 1040633 A1 HK1040633 A1 HK 1040633A1 HK 02102308 A HK02102308 A HK 02102308A HK 02102308 A HK02102308 A HK 02102308A HK 1040633 A1 HK1040633 A1 HK 1040633A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- therapeutic compound
- drug resistant
- composition
- administering
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11300498P | 1998-12-18 | 1998-12-18 | |
PCT/US1999/030230 WO2000035422A2 (en) | 1998-12-18 | 1999-12-17 | Method of administering a compound to multi-drug resistant cells |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1040633A1 true HK1040633A1 (en) | 2002-06-21 |
Family
ID=22347057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK02102308A HK1040633A1 (en) | 1998-12-18 | 2002-03-26 | Method of administering a compound to multi-drug resistant cells |
Country Status (12)
Country | Link |
---|---|
US (2) | US20040161457A1 (xx) |
EP (1) | EP1140022B8 (xx) |
JP (1) | JP2002532407A (xx) |
AT (1) | ATE385778T1 (xx) |
AU (1) | AU769569B2 (xx) |
CA (1) | CA2353593A1 (xx) |
DE (1) | DE69938148T2 (xx) |
ES (1) | ES2302391T3 (xx) |
HK (1) | HK1040633A1 (xx) |
IL (1) | IL143555A0 (xx) |
MX (1) | MXPA01006201A (xx) |
WO (1) | WO2000035422A2 (xx) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ014799A0 (en) * | 1999-05-04 | 1999-05-27 | Access Pharmaceuticals Australia Pty Limited | Amplification of folate-mediated targeting to tumor cells using polymers |
AU2001244713A1 (en) * | 2000-04-03 | 2001-10-15 | Santen Pharmaceutical Co. Ltd. | Transporters and drug delivery system by using the same |
JP4922824B2 (ja) * | 2000-04-03 | 2012-04-25 | 参天製薬株式会社 | 送達性物質およびそれを利用した薬物デリバリーシステム |
CA2510780A1 (en) * | 2002-12-19 | 2004-07-08 | Alza Corporation | Method of treating angiogenic tissue growth |
DK1592457T3 (da) | 2003-01-27 | 2012-10-22 | Endocyte Inc | Folat-vinblastin-konjugat som lægemiddel |
CN100423778C (zh) * | 2003-11-25 | 2008-10-08 | 上海复旦张江生物医药股份有限公司 | 用于上载抗肿瘤药物的脂质体载体及其制备方法和应用 |
JP5149620B2 (ja) | 2004-07-23 | 2013-02-20 | エンドサイト,インコーポレイテッド | 2価リンカーおよびその結合体 |
US20070292497A1 (en) * | 2006-05-04 | 2007-12-20 | Martin Francis J | Method for treating micrometastatic tumors |
WO2008112873A2 (en) | 2007-03-14 | 2008-09-18 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
SI2308514T1 (sl) * | 2007-03-23 | 2013-09-30 | To-Bbb Holding B.V. | Konjugati za prenos zdravila preko krvno-moĹľganske pregrade |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
CN104383553A (zh) | 2007-06-25 | 2015-03-04 | 恩多塞特公司 | 含有亲水性间隔区接头的共轭物 |
EP2209374B1 (en) | 2007-10-25 | 2014-12-03 | Endocyte, Inc. | Tubulysins and processes for preparing |
US20120100206A1 (en) | 2009-06-11 | 2012-04-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Targeted liposomes comprising n-containing bisphosphonates and uses thereof |
LT2731591T (lt) | 2011-07-13 | 2020-12-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Liposomos, kuriose kartu inkapsuliuotas bisfosfonatas ir amfipatinis agentas |
CA2858741C (en) | 2011-12-07 | 2018-07-31 | Universidade Do Minho | Folate-targeted liposomes |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
GB201215289D0 (en) * | 2012-08-28 | 2012-10-10 | Medical Res Council | Nanoparticle formulation |
US9950074B2 (en) * | 2012-10-12 | 2018-04-24 | Georg-August-Universität Göttingen Stiftung Öffenlichen Rechts, Universitätsmedizin | Composition and delivery vehicle for active agents and methods therefor |
BR112015008365A2 (pt) | 2012-10-16 | 2017-07-04 | Endocyte Inc | composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente |
CN106420615B (zh) * | 2016-07-05 | 2021-01-05 | 广东药科大学 | 一种靶向脂质体骨架材料及其制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5108921A (en) * | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US6113946A (en) * | 1992-04-03 | 2000-09-05 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system comprising dendrimer polycations |
US5858397A (en) * | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
US5804445A (en) * | 1996-01-11 | 1998-09-08 | Board Of Regents, The University Of Texas System | High affinity mutants of nuclear factor-interleukin 6 and methods of use therefor |
WO1998013072A1 (en) * | 1996-09-24 | 1998-04-02 | Thomas Jefferson University | Compositions for and methods of treating multiple drug resistance |
US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
TW520297B (en) * | 1996-10-11 | 2003-02-11 | Sequus Pharm Inc | Fusogenic liposome composition and method |
US6162810A (en) * | 1997-11-17 | 2000-12-19 | The Regents Of The University Of California | Inadone and tetralone compounds for inhibiting cell proliferation |
US6426086B1 (en) * | 1998-02-03 | 2002-07-30 | The Regents Of The University Of California | pH-sensitive, serum-stable liposomes |
IT1315253B1 (it) * | 1999-10-22 | 2003-02-03 | Novuspharma Spa | Preparazione liposomiale di 6,9-bis-(2-amminoetil)ammino|benzog|isochinolin-5,10-dione dimaleato |
CA2537520A1 (en) * | 2003-09-24 | 2005-04-07 | Wyeth Holdings Corporation | 6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents |
-
1999
- 1999-12-17 AU AU19404/00A patent/AU769569B2/en not_active Ceased
- 1999-12-17 JP JP2000587743A patent/JP2002532407A/ja not_active Withdrawn
- 1999-12-17 CA CA002353593A patent/CA2353593A1/en not_active Abandoned
- 1999-12-17 AT AT99963103T patent/ATE385778T1/de not_active IP Right Cessation
- 1999-12-17 DE DE69938148T patent/DE69938148T2/de not_active Expired - Fee Related
- 1999-12-17 WO PCT/US1999/030230 patent/WO2000035422A2/en active IP Right Grant
- 1999-12-17 IL IL14355599A patent/IL143555A0/xx unknown
- 1999-12-17 ES ES99963103T patent/ES2302391T3/es not_active Expired - Lifetime
- 1999-12-17 MX MXPA01006201A patent/MXPA01006201A/es not_active Application Discontinuation
- 1999-12-17 EP EP99963103A patent/EP1140022B8/en not_active Expired - Lifetime
-
2002
- 2002-03-26 HK HK02102308A patent/HK1040633A1/xx not_active IP Right Cessation
-
2004
- 2004-02-13 US US10/778,738 patent/US20040161457A1/en not_active Abandoned
-
2005
- 2005-09-06 US US11/220,901 patent/US20060062842A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2002532407A (ja) | 2002-10-02 |
AU1940400A (en) | 2000-07-03 |
WO2000035422A3 (en) | 2000-10-12 |
CA2353593A1 (en) | 2000-06-22 |
EP1140022A2 (en) | 2001-10-10 |
AU769569B2 (en) | 2004-01-29 |
MXPA01006201A (es) | 2003-06-06 |
DE69938148D1 (de) | 2008-03-27 |
DE69938148T2 (de) | 2009-02-26 |
ATE385778T1 (de) | 2008-03-15 |
WO2000035422A2 (en) | 2000-06-22 |
EP1140022B8 (en) | 2008-10-15 |
IL143555A0 (en) | 2002-04-21 |
US20060062842A1 (en) | 2006-03-23 |
US20040161457A1 (en) | 2004-08-19 |
ES2302391T3 (es) | 2008-07-01 |
EP1140022B1 (en) | 2008-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1140022B8 (en) | Method of administering a compound to multi-drug resistant cells | |
IL142573A0 (en) | Liposome-entrapped topoisomerase inhibitors | |
WO1998016202B1 (en) | Fusogenic liposome composition and method | |
WO1999039741A3 (en) | Systemic delivery of serum stable plasmid lipid particles for cancer therapy | |
WO2000045792A8 (en) | Hydrogel particle formulations | |
AU2709495A (en) | Sphingosomes for enhanced drug delivery | |
WO2000007979A3 (en) | Compounds and compositions for delivering active agents | |
AU5408098A (en) | Oral morphine multiparticulate formulation | |
WO2002022000A3 (en) | Targeted alpha particle therapy using actinium-225 conjugates | |
CA2338358A1 (en) | Compounds and compositions for delivering active agents | |
WO2001080843A3 (en) | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same | |
UA50719C2 (uk) | Проліки для терапії пухлин і запальних захворювань | |
CA2628857A1 (en) | Formulation and method for treating neoplasms by inhalation | |
CA2208206A1 (en) | Composition for treating tumors comprising lactose and a saccharide conjugate of a cytotoxic phenolic compound | |
WO1995030423A3 (en) | Cancer treatment and metastasis prevention | |
WO1999013816A3 (en) | Liposomal camptothecin formulations | |
EP2020237A3 (en) | Ceramide and chemotherapeutic agents for inducing cell death | |
CA2202531A1 (en) | Lyophilizate of lipid complex of water insoluble camptothecins | |
JP2002532407A5 (xx) | ||
Zou et al. | Effectiveness of water soluble poly (L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice | |
CA2108963A1 (en) | Compositions and Methods for Therapy and Prevention of Cancer, Aids and Anemia | |
WO1999022722A3 (en) | Use of macrolides for the treatment of cancer and macular degeneration | |
WO1998030709A3 (en) | Non-immunogenic prodrugs and selectable markers for use in gene therapy | |
Sharma et al. | Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers | |
CA2225807A1 (en) | Use of lamellarin-class alkaloids in methods of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHPA | Change of a particular in the register (except of change of ownership) | ||
PE | Patent expired |
Effective date: 20191216 |